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Preimplantation genetic diagnosis (PGD) is publicly funded in New Zealand from 2006.  PGD 
poses a range of issues that have ongoing significance for other later emerging applications 
of genetic technologies arising from the sequencing of the human genome.  The idea of the 
‘designer baby’ is the most publicly proclaimed outcome of new developments in genetic 
medicine.
Professor Gareth Jones cites the following as examples of how the public imaginations and 
fears are fed.1  The first is from a hoax website:
“Dear Prospective Parent
Thank you for considering GenoChoice to plan the future well-being of you and your 
family.  My name is Dr Elizabeth Preatner, a prenatal geneticist and embryologist here at 
GenoChoice.  Using our state-of-the-art technologies, you can quite possibly ensure that 
your child’s life may be free of such diseases as cancer, Alzheimer’s, and heart disease – as 
well as conditions like obesity, aggression, and dyslexia.  And you can even specifically 
choose genes that may determine favorable characteristics in your child”.2
The second is from Joel Garreau:
“We are at a turning point in history.  For millenniums our technologies … have been 
aimed at modifying our environment.  Now, for the first time, our technologies are 
increasingly aimed inward – at altering our minds, memories, metabolisms, personalities, 
and progeny.  This is not some science fiction future.  Inexorable increases in ingenuity are 
opening vistas, especially in what we may call GRIN – genetic, robotic, information and 
non – technologies”.3
Professor Jones also cites the German philosopher, Jurgen Habermas, who views PGD as 
being:
“based on a judgment of the quality of a human being and therefore expresses a desire for 
genetic optimisation.  An act that in the end leads to the selection of a healthier organism 
issues from the same attitude as a eugenic praxis”.
Professor Jones argues persuasively that distinctions between medical therapy and enhancement, 
normality and abnormality, health and disability, are not clearly defined.  They change over 
time and between societies – “all of us, when compared with our forebears, are enhanced”.  He 
emphasises that “what is lacking from so much debate in this area is a lack of what is or is not 
scientifically feasible … there are differences of kind between PGD and designing the perfect 
baby”.
The title of our report: Choosing Genes For Future Children – Regulating and Preimplantation 
Genetic Diagnosis has been carefully selected   We want the report to be accurate about what is 
being done.  It is possible, using PGD, to choose that a baby will not have genes for a particular 
genetic disorder.
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There is no societal unanimity on the answers to the ethical and moral questions that are 
raised by the use of PGD.  When artificial insemination was first possible, a Royal Commission 
was set up in the United Kingdom to see whether it should be made a criminal offence. 
Now the technology is widespread throughout the world.  Our society places high value on 
individual choice and autonomy, yet there are times when individual choice and autonomy are 
perceived to harm the community as a whole – at which point that is reached is rarely a matter 
of common agreement.
The Hippocratic Oath, which states “I will follow treatments which according to my ability 
and judgment I consider for the benefit of my patients and abstain from whatever is harmful”, 
does not provide all the answers to the complexities of the issues that PGD raise.  The concepts 
of “benefit” and “harm” are not neutral and depend very much on the perspective of whoever 
is looking at them.
It would be too simplistic if the choice were between either opting for a broad-brush approach 
of greatest caution reinforced by State control until such time as we have foreseen and tested 
all the possible risks and concerns of the use of PGD, or an ultra-liberal approach of non-
interference until it is clearly proven there are risks and harms that everyone agrees upon.
In the past, both such approaches have led to negative consequences in particular contexts. 
For example, in the 1930s in the United States of America, over 20,000 people who the United 
States government believed were “undesirables” were sterilised against their will as a precaution 
against them having children.  The case of Buck v Bell 4 in 1924 concerned three generations: 
a mother Emma Buck, her daughter Carrie Buck, and a granddaughter Vivian Buck who lived 
in a “colony for epileptics and feeble-minded” in Virginia.  Emma Buck’s sister Doris was also 
part of the case.  They were all deemed to be mentally defective by an IQ test (the Binet test). 
Vivian was only seven months old at the time of “testing” but was reported to have a “look” 
about her which was not quite “normal”.  This was sufficient evidence to convince Justice 
Oliver Wendell Holmes in the United States Supreme Court to declare “three generations of 
imbeciles are enough”.
Doris and Carrie were duly sterilised.  The upshot of the 1924 decision in Buck v Bell was that 
by 1931, 27 other States enacted sterilisation laws to prevent the “undesirable classes” from 
reproducing.  The laws provided for the compulsory sterilisation of certain classes of people 
thought to be insane, feeble-minded or epileptic, habitual criminals and moral perverts. 
Vivian, Carrie Buck’s daughter, went through second grade at high school where her teachers 
reported her to be very bright.  Doris Buck was never told the real nature of the operation; 
simply that it had been for a burst appendix.  David Galton5 says that when Doris Buck learned 
the truth she said: “I broke down and cried.  My husband and me wanted children desperately. 
We were crazy about them.  I never knew what they’d done to me.”  The individual is harmed 
in the mistaken belief the State will benefit.
At a similar time in the United States, in 1932,6 the individual unregulated choices of medical 
researchers had a massive impact on 400 African-Americans who had signs of syphilis in the 
infamous Tuskegee Syphilis Study.  The 400 African-American research subjects were observed 
for 40 years to see how syphilis progressed in them.  They did not know the nature of the 
experiment nor were they told after 1945 that penicillin could treat their condition.  By 1955, 
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one-third of the research subjects were dead from syphilis.  In the 1970s, this public health 
scandal was brought to light when medical papers were published about the experiment.  A 
civil rights action was filed against the United States Public Health Service and was settled 
out of court for more than US$9 million.  It took until President Clinton’s presidency for an 
apology to be issued on behalf of the US Government to the surviving victims.  The freedom 
of the researchers to research as they saw fit led to cruel and inhumane harm to the subjects 
of the research.
In New Zealand, in 1987, the Committee of Inquiry into Allegations Concerning the Treatment 
of Cervical Cancer at National Women’s Hospital and into Other Related Matters (the 
Cartwright Inquiry) found that an experimental research programme conducted by Dr Green 
in the 1960s and  1970s at the National Women’s Hospital in Auckland resulted in inadequate 
treatment for many women.7  The research involved withholding conventional treatment from 
patients with carcinoma in situ of the cervix in order to study the natural course of the disease. 
About 40 of the women patients eventually developed invasive cancer.
The best way to develop good regulatory policy is to consider as many viewpoints as possible 
in a fair and even-handed manner.  The final decision to regulate or not is for the government 
to consider, decide and act.  Our task is to present the viewpoints and regulatory options with 
compassion and to analyse them as best we can without bias.  Our hope is that the tone of this 
report will, at the very least, enable readers to empathise with interests and concerns that go 
against their own interests and concerns.  For a community to work through potentially deeply 
divisive issues, it is crucial that an attitude of seeing the concerns of others in their best light 
is cultivated.  This is not the same as giving up one’s own values and committing to the values 
and beliefs that give a particular concern force.  Dr Anthony T Kronman has said:
“Only the person who has surveyed, with sympathetic detachment, the conflicting 
interpretations that different members of his community offer of its goals is in a position 
to say whether his own preliminary views should be revised and to make an informed 
choice among the alternatives before him”.8
There is an incommensurable diversity of human goods and no overriding objective criterion 
to definitively rank them.  If there are no rational grounds for insisting that one view of the 
good is superior to those of others, then forced suppression of a particular belief or practice 
leads to the loss of something humanly valuable.
The investigators and researchers working on this Project do not represent any particular 
political party, religion, belief or government policy.  They are all independent and diverse 
thinkers who bring to the Project a spirit of open inquiry and empathy for different viewpoints 
and dispassionate (as is humanly possible) analysis.
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tHe science anD clinical utilisation oF PgD
PGD was developed as an alternative to prenatal diagnosis for couples who were at risk of passing 
inherited diseases to their children.  With prenatal testing utilising chorionic villus sampling 
(CVS) or amniocentesis, diagnosis is undertaken when pregnancy is already established.  If 
the foetus is affected then parents may consider whether to continue with the pregnancy or to 
terminate it.  Hence, when compared with prenatal diagnosis, PGD substantially minimises or 
avoids the need for termination.
Research in the UK on PGD began in the mid-1980s to help couples who wished to have 
diagnosis for inherited disease before embryo implantation instead of during pregnancy. 
Preimplantation testing techniques were not new then but had been carried out on non-
human embryos since 1968 and were used routinely in the context of animal husbandry to 
breed animals of the preferred sex.9
The first successful human pregnancies using PGD were reported in 1990 for various X-linked 
or sex-linked disorders (where males, not females are affected) with the selection of female 
embryos for implantation. This was followed by the report in 1992 of a live birth after utilising 
PGD selection against cystic fibrosis, which is an autosomal disease where both copies of a 
gene are non-functional.10
By 2000, PGD had been used in the UK to test for a range of disorders caused by a single gene, 
e.g. beta-thalassaemia, sickle cell anaemia and muscular dystrophy, and for chromosomal 
abnormalities, e.g. Down, Turners and Edwards syndromes.11
PGD involves the creation of embryos, embryo biopsy, analysis of one or two biopsied cells, 
and transfer of unaffected embryo(s) to establish pregnancy.  PGD incorporates the use of IVF 
technology as part of the process.
Embryos are created by injecting a single sperm into each oocyte to achieve fertilisation.  This 
technique, intracytoplasmic sperm injection (ICSI), is used in the majority of cycles of PGD, 
to avoid contaminating sperm interfering with the PCR analysis.
After fertilisation, embryos are cultured and then embryo biopsy carried out.  This involves 
taking one or two cells from an embryo, two to four days after fertilisation.  In some instances, 
polar body biopsy, involving the analysis of polar body cells resulting from oocyte development, 
is used.  The polar bodies give an indication of the genetic composition of the egg.  Polar body 
biopsies are used in countries where embryo biopsy is prohibited.
Single cell diagnosis is then performed using the polymerase chain reaction (PCR) or 
fluorescent in situ hybridisation (FISH), depending on the disorder being diagnosed.
PCR is the exponential amplification of a specific region of DNA and is used to analyse small 
changes in DNA in a single gene.  Each new mutation requires the development of a new PCR 
test.  In addition, because it is such a sensitive technique and because the target is so small, 
contamination has to be carefully avoided.  A technique called whole genome amplification 
(WGA) is a way of increasing the amount of template for the PCR reaction from just one copy 
of the genome to many.  PCR is also hampered by a phenomenon known as ‘allele dropout’ 
(ADO) or ‘preferential amplification’ which happens when an allele being examined fails to 
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amplify.  In a carrier, for example, only the normal or only the affected allele is amplified rather 
than both alleles equally.  Analysis of areas either side of the mutation (also using PCR) control 
for this phenomenon.
FISH is used to analyse chromosome numbers and gross abnormalities and for sex selection 
mainly for X-linked disorders.  It can easily be used for non-medical sex selection, the use of 
which is illegal in NZ currently.
PGD started with the purpose of identifying embryos that have the genetic mutations for 
serious, life threatening conditions.  PGD can also be used to help women with a history of 
recurrent miscarriages or of advanced maternal age to reduce the rate of miscarriage.  Embryos 
are biopsied and screened for changes in chromosomal numbers (aneuploidy12) and only 
those embryos with a normal number of chromosomes are transferred.  This is by far the most 
common use of the technology according to recent figures13 but this use of the technology is 
not publicly funded in New Zealand.  On the basis of what is presently known in terms of the 
science and technological ability, screening for aneuploidy is not sufficiently determinative of 
a guaranteed outcome.
PGD has subsequently been used to select a tissue-matched or HLA compatible embryo for 
the purpose of having a child who will be a match for an existing sick sibling for a stem cell 
transplant from the umbilical cord.
In 1997, a PGD consortium was formed as part of the European Society of Human Reproduction 
and Embryology (ESHRE) to undertake long-term study of the efficacy and clinical outcomes 
of PGD.  The ESHRE PGD Consortium started collating data from 25 centres (increasing to 66 
centres by 2005) from Europe and six other countries and on referrals, cycles, pregnancies and 
babies born after PGD.  Reports have been published in 1999, 2000, 2002 and 2005, covering 
data up to 2002.14
Recognising variations in local or national regulations and specific laboratory practices, and 
acknowledging that differences will remain with regard to the ways in which PGD is practised, 
the ESHRE PGD Consortium recently provided guidelines in the hope that higher quality 
overall and standardisation of PGD can be achieved by building consensus opinion within the 
PGD community on best practices based on available evidence.15
A study of the past 12 years of data from the world’s three largest PGD centres, comprising 
4748 PGD attempts and 754 successful pregnancies, led to the conclusion that PGD is safe.16
PGD is not yet a widely used procedure but seems likely to become more popular both as 
people become aware of its availability and as the number of conditions for which testing is 
available expands.  New Zealand is unique amongst countries offering PGD services, given 
its commitment to funding the full cost of up to two cycles of IVF/PGD for people who use 
PGD to test for serious inherited genetic disorders.   This funding includes the costs of the 
IVF treatment that must accompany PGD.17  While the embryo biopsy can now be performed 
in New Zealand, many of the tests are conducted on a contracted-out basis at Monash IVF in 
Australia.  Monash IVF is contracted to provide tests for five major conditions18 and also offers 
aneuploidy screening – any testing beyond these can be done on a case-by-case basis.
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The question of whether or not New Zealand develops a full capability for this technology is 
likely to be dependent on the actual and projected uptake by the population.  PGD is a highly 
specialised technique and requires skilled personnel.   Staff competence and skill maintenance 
will be vital to the provision of this service in order to maximise safety and efficiency, yet 
New Zealand has challenges to overcome, for example, in terms of offering competitive and 
attractive remuneration by comparison with other countries.  It has been noted, for instance, 
that “New Zealand has traditionally had difficulty recruiting and retaining geneticists, mainly 
because of professional isolation.”19
MÄori PersPectives on PgD
Mäori are the tangata whenua – the indigenous people of New Zealand.  The Treaty of Waitangi 
1840, a treaty signed between Mäori chiefs and representatives of the British government, and 
the principles of the Treaty create and continue to re-create the unique relationship between 
the Crown and Mäori in New Zealand.20   Mäori concerns about PGD hinge partly on the 
concern that the principles of the Treaty may have been undermined by the Human Assisted 
Reproductive Technology Act 2004 (the HART Act) and the Guidelines on Pre-implantation 
Genetic Diagnosis (the Guidelines) in that neither the legislation nor the Guidelines make 
express reference to the Treaty of Waitangi, nor do they provide sufficiently adequate account 
of the ethical basis for how culturally-based decisions may be undertaken or implemented 
consistent with tikanga Mäori.
The HART Act does, however, state that the needs, values and beliefs of Mäori should be 
considered and treated with respect, and that the different ethical spiritual and cultural 
perspectives in society should be considered and treated with respect.
Cultural values that underpin a Mäori way of being and the place of Mäori in the universe 
are established by virtue of their whakapapa (genetic inheritance).  The authority of a group 
to make collective decisions about the best interest of its members, individual autonomy, or 
self-governance, is based on the ability of a group to govern themselves.  Ultimately, Mäori 
acknowledge that an individual has a right to use PGD, but the collective asserts its authority 
to protect its whakapapa – as a taonga under Article II of the Treaty of Waitangi.
A pioneering study of ethical, spiritual, cultural and social issues pertaining to pre-birth genetic 
testing from a Mäori perspective was carried out by the Mäori research team collaborating 
with this project.  The study involved in-depth interviews with a range of Mäori participants. 
No single Mäori view on the potential risks and benefits of pre-birth genetic testing is offered 
although strong patterns of agreement on aspects of the potential risks and benefits emerged. 
There was general agreement that PGD has the potential to do more good than harm for 
Mäori communities.  There was also general agreement and concern that Mäori may not have 
equity of access to PGD.  The most pressing concern for Mäori is working at the balance 
between individual and collective rights to the use of PGD and creating an environment where 
this can happen.
A cultural decision-making framework based on tikanga Mäori to help with assessing the risks 
and benefits of PGD in a culturally appropriate way is proposed.21  The framework provides 
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a position for assessing a situation or event that challenges thinking and values, using key 
concepts (such as tapu, mauri, take, utu, whanautanga, manaakitanga, mana, tika and noa)22 
relating to tikanga Mäori.
Respect for cultural priorities is an extremely important consideration in the regulation of 
genetic services in New Zealand.  A role of any regulatory regime is therefore to support the 
expression of tikanga Mäori in the modern world, enabling the present generation of Mäori to 
reproduce according to the spiritual and philosophical understandings of their ancestors
etHical PrinciPles
The fact that embryos are specifically created for selection in the use of PGD entails their possible 
rejection. This, rather than the PGD activity itself, is thought by some to be objectionable as it 
is said to instrumentalise embryos.  Equally, other arguments are used by opponents of PGD, 
for example that it may have negative effects on resultant children and that there may be risks 
to the child’s physical and/or emotional status. The emotional risks would be the hardest to 
quantify but some believe that the power of choice put into the hands of parents by PGD 
could alter the parent/child relationship fundamentally from one of unconditional love to one 
dictated by the realisation (or not) of specific ‘designer’ expectations.
There are a number of arguments against PGD.  One of them is the ‘Playing God’ objection 
which is examined from the Christian viewpoints, and from the secular standpoint in terms of 
interfering with the natural order.
There is a plurality of Christian views of PGD ranging from the conservative proscriptive 
position to the modern facilitative position of engaging with God in His creative activity.  The 
conservative view holds that to engage in PGD is to reject God’s image in His creation; it is to 
reject human life as a gift and transform it into a humanly designed product. Each of these 
undermines the dignity of human beings and their unconditional worth. This is, however, a 
minority view.  The modern facilitative view is that people are seen as co-creators with God 
to realise the existence of a better world. On this basis PGD, is not ruled out per se but is 
limited to applications which are ‘good’.  The challenge lies in identifying which applications 
are ‘good’.
A difficulty with the ‘Playing God’ objection is the level of uncertainty attaching to Christian 
views because of the wide range of views about God and the Christian moral order. These 
make the objection equivocal.  Furthermore, the Christian justifications for intervening 
in human life in many areas, including modern medicine, to avoid agonies being suffered 
by people, make it inconsistent to avoid by means of PGD the intractable and unbearable 
suffering brought about by serious incurable genetic disorders.
Secular substitutes for the Playing God criticism of PGD take the form of claiming that it 
amounts to an unnatural intrusion into procreation and therefore is an invitation to risks 
such as reduction in biodiversity. This criticism is countered, first, by an appeal to the fact 
that interference in breeding over centuries has not had this effect and, second, that the small 
numbers involved in PGD could not produce such an effect.   The claim that interference 
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with nature entailed by PGD would produce a slippery slope to eugenics is an empirical claim 
which lacks evidence in that other similar reproductive technological innovations have been 
successfully regulated by public consensus.
The conservative view of the embryo as having the full moral status of a person proscribes 
PGD.  On the other hand, the liberal view that no moral status is accorded to the embryo or 
foetus places no barriers on what should be done to them. Between these views, the moderate 
view sees the developing embryo and foetus as growing in moral status throughout gestation 
and calls for limits to the use of PGD but not its proscription.
The wide and differing range of views held by the general public on the status of the embryo 
and foetus cannot be ignored.  New Zealand legislation already permits abortion and PGD on 
limited grounds, and so does not reflect the conservative view of the foetus although the limits 
imposed might be construed as opposing a completely liberal view.   There are no conclusive 
arguments, nor is there any crucial evidence, which can resolve the differences in views from 
various accounts of the status of the human embryo and foetus.  The question of whether PGD 
should or should not be permitted is ultimately not usefully addressed by seeking an answer to 
the question of the status of the human embryo or foetus.
The moderate or ‘gradualist’ approach to the human embryo – an approach that sees the 
embryo as more than a mere collection of cells, but as less than a full person – is adopted in 
this report.   This approach requires that the embryo of the human species is worthy of respect 
at all stages, but that certain interventions/treatments may be permissible at certain stages, 
with the limits of permissibility narrowing as the embryo/foetus nears maturity.
Selecting embryos on the basis of their genetic status is a matter of considerable concern for 
many people – particularly those speaking for the disability rights community.  Attitudes vary 
as to whether or not the availability of PGD to screen out genetic conditions will result in 
disrespecting people with disabilities or whether this use of PGD sends out a eugenics signal. 
For some, it is inevitable that the ability to choose to discard affected embryos means that those 
currently living with the relevant condition are disrespected; that their lives are regarded as less 
worthy.  There is a lack of empirical evidence to support one case or the other.
Proponents of PGD contend that it is the disability and not the disabled that we are seeking to 
avoid.   On this argument, there need be no negative impact on those living with disability.
Equally, the eugenic argument is asserted strongly by some, while others would distinguish 
individual rights to make choices from the state-sponsored eugenic programmes which were 
in place in the United States and, most especially, Nazi Germany in the early parts of the 20th 
Century.   For example, the House of Commons Select Committee on Science and Technology 
took issue with the negative connotations of the word ‘eugenics’, saying:
“If ensuring that your child is less likely to face a debilitating disease in the course of 
their life can be termed eugenics, we have no problems with its use: state programmes 
that impose a genetic blueprint are another matter.  They should be outlawed as part of 
any regulation of assisted reproduction.  Use of the word eugenics must not be used as an 
emotive term of abuse to obscure rational debate”.23
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Discussions about these issues in New Zealand are emerging.  The New Zealand Organisation 
for Rare Disorders is open to the use of emerging genetic technologies for parents to choose 
to avoid the birth of children with disabilities.  For the Crippled Children’s Society, their focus 
has been to consider changing their constitution to emphasise that they celebrate the lives of 
people with disabilities.
The place of people with disabilities and the impact of clinical advance on their position is 
sometimes seen to be somewhat marginalised, and surely deserves special protection.   New 
Zealand does not have a Disability Rights Commission (as, for example, the UK does) although 
it has a Minister for Disability and an Office for Disability Issues.  Additionally, even with a 
number of statutes relevant in this area (the New Zealand Bill of Rights Act 1990, Human 
Rights Act 1993, and Health and Disability Commissioner Act 1994), New Zealand has no 
body directly responsible for issues that fall under the category of promoting good relations 
between people with disabilities and their communities.24
The bioethical analyses are informed by the Universal Declaration of Bioethics and Human 
Rights (UDBHR)25 which significantly focuses on the inter-relationship between bioethics and 
human rights, and helps shape thinking and reflection for both the process of developing 
policy and determining the content of policy.  At the heart of the ethical analysis of PGD is the 
tension between, on one hand, individual freedom and privacy to make reproductive choices 
and, on the other hand, social solidarity and responsibility to ensure that human dignity is not 
eroded or undermined.
law
The assessment of legislative frameworks in this report is based on principles which are most 
likely to enable regulatory initiatives to be accepted by the general public as legitimate.  These 
principles require that the regulatory framework must be proportionate to the perceived harms 
or risks posed to justify the imposition of regulatory limits.  Regulators should have clear lines 
of accountability, in particular, their decisions must be justified and be subject to public scrutiny. 
There should be accessible, fair and effective complaints and appeals processes.   Consistency in 
administering the regulation and in the regulation itself, and transparency in terms of what the 
regulatory objective is, and the legal obligations of those being regulated are essential.  Finally, 
regulation must be precisely targeted to achieve its objective.
In comparison to other regimes with similar regulatory structures, New Zealand is unique 
in that the HART Act establishes two statutory bodies with clear remits.  New Zealand has 
therefore departed from the international trend of having one statutory authority that both 
creates and implements policy.  Instead there are two bodies:  an advisory committee which 
creates policy, and an ethics committee which assesses individual cases against the advisory 
committee’s guidelines.  The main benefit of this structure is that focusing solely on policy 
increases the efficiency of the Advisory Committee’s policy-making process, both in terms of 
time and the expertise of those creating policy.
New Zealand is different from the jurisdictions used here as comparators in that it has 
essentially de-regulated some aspects of assisted reproduction.  The UK Human Fertilisation 
and Embryology Authority26 is presently arguing for more rather than less inclusive regulation. 
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The mechanism governing ‘established procedures’ in the HART Act allows certain procedures 
to be carried out without external scrutiny and indicates to that extent a commitment to 
imposing only such regulatory restraint as is seen to be necessary.  The fact that it is an offence 
to perform an established procedure unless the provider is certified under the Health and 
Disability Services (Safety) Act 2001 shows there is emphasis on ensuring that appropriate 
clinical standards are observed and patient safety is maintained.  A further difference in the 
New Zealand legislation is that it has not adopted a licensing system.  Instead, it has built on 
existing health and safety requirements, making certification under the Health and Disability 
Services (Safety) Act 2001 a statutory requirement and providing civil sanctions for non-
compliance.  There is no explicit provision allowing for conscientious objection within the 
regulatory framework for PGD that recognises circumstances where a segment of providers 
and the public may not wish to be involved because of, for example, religious or personal 
moral beliefs.27
There is as yet no provision for applicants to appear before the Ethics Committee when 
presenting their case (a right which has recently been made available in the United Kingdom). 
This may perhaps be an unfortunate omission, particularly as the Ethics Committee exercises 
the function of applying policy and making decisions affecting individual citizens coming 
before it.  Allowing an explicit process that provides the opportunity for applicants to speak to 
their case would render decisions more transparent, and build more confidence and trust in 
the process.  There is no right of appeal from a decision of the Ethics Committee – such a right 
exists in both the UK and the state of Victoria.
The report identifies issues of inconsistency in the legislation and policy development within 
the context of the legislation.  The creation of a category of ‘established procedures’ reflected 
an apparent desire not to regulate unnecessarily, yet it is arguable that the outright ban on non-
medical sex selection is unnecessarily rigid, particularly as public and other attitudes can and 
do shift rapidly.  The ‘established procedures’ category is potentially broad enough to capture 
late-onset and susceptibility disorders, such as those involving BRCA1 and BRCA2 mutations 
which are transmitted in an autosomal dominant pattern in families.  Carriers of the mutations 
have a 60% to 90% risk of developing breast cancer, compared with a 10% risk in the general 
population.  This may not have been intended but the wording of ‘serious impairment’ is 
broad enough to cover this situation.  The determination of ‘serious impairment’ under the 
‘established procedures’ category is solely a medical one at present in New Zealand.  By way of 
contrast in the UK, the determination is made in collaboration with the family who have a say 
into the decision about PGD use.
Selection of embryos with a genetic impairment seen in a parent is prohibited by the Guidelines. 
The implication of this, by contrast, is inconsistent with prenatal testing where parents can 
choose to continue with the pregnancy when aware of genetic impairment in a foetus.
The Guidelines which set out the lawful parameters of PGD in conjunction with HLA tissue 
typing are problematic on several fronts.  The Guidelines require that the planned treatment for 
the affected child will utilise only the cord blood of the future sibling.  Yet medical procedures 
carried out on a child, such as bone marrow donation, do not come within the jurisdiction 
of the policy-making body under the HART Act 2004.  In New Zealand, medical procedures 
carried out on a child are covered by other established healthcare law and principles.
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The effect of the Guidelines is that an embryo may be tested for HLA compatibility as an 
add-on procedure if embryo biopsy is indicated to test for the presence of a genetic disorder 
in the prospective offspring.  However, tissue typing may not be carried out as an additional 
procedure if the affected child is suffering from a non-genetically heritable condition, regardless 
of whether embryo biopsy is indicated to test for the presence of a familial single gene or familial 
chromosomal disorder in the embryo.   It is unlikely this was an intended consequence by those 
responsible for the Guidelines. The anomaly may be easily rectified by requiring only that the 
affected child is suffering from a severe life-threatening condition.  Regulating HLA tissue typing 
so narrowly is in tension with the minimal evidence of risk to the embryo, particularly when a 
wide range of PGD uses are already permitted as established procedures.
All of the policy formulated via and pursuant to the Act has been based purely on therapeutic 
applications of PGD technology. Although there has been an intention expressed by the Select 
Committee that PGD should not be used for selection of non-medical traits, this has not 
been expressly stated in the Act.  While the prohibitions in Schedule One of the Act prohibit 
reproductive research, they do not prohibit the conduct of non-reproductive research which 
may be permitted should the Advisory Committee promulgate guidelines.28
The terms of reference provided by the Minister for the Advisory Committee evoke some 
concerns.  Decisions of the Advisory Committee may be made by simple majority vote.  This may 
be criticised by some but it is the robustness of the debate that is important. Understandably, 
perhaps, the members are restrained from publicly expressing any disagreement with policy 
decisions.  It would increase transparency, and thereby promote public confidence in the 
legitimacy of the Committee and the process, if decisions of the Committee were accompanied 
by reasoned analysis of the decisions reached, including the scientific basis, the differing 
perspectives taken into account, the number of members in favour or against (or abstaining 
from) decisions that are made, and the opportunity for dissenting individual members to 
record and append their comments to the final decision of the Committee.
There are strong grounds to believe that the decision-making process of the Ethics Committee 
as set out in the Terms of Reference for ECART is ultra vires.  The HART Act, in effect, 
requires the Ethics Committee to be subject to the Operational Standard for Ethics Committees 
(the Operational Standard). The Minister’s terms of reference permit decision-making on 
the grounds of a two-third majority, contrary to the Operational Standard which requires 
consensus decision-making.  This leaves any decision made by them open to challenge by way 
of judicial review on the grounds of procedural invalidity.  In addition, the Act requires that 
the Minister must ensure the committee complies in its composition with the Operational 
Standard which requires a minimum of 10 members.  However, the Terms of Reference for the 
Ethics Committee provide only for 8 members as a minimum, and the committee is currently 
constituted with 8 members.  It is possible, therefore, that ECART may be open to challenge as 
being not legally constituted under the Act.
It is a concern that, although the Advisory Committee has been given the mandate and duty 
to monitor the application and health outcomes of assisted reproductive procedures and 
research, a robust medium- or long-term monitoring system has not been put in place before, 
or at the same time as, PGD has been declared to be an established procedure.
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There is little doubt that the HART Act 2004 was a necessary legislative initiative.  The 
framework sets up affordable, efficient and responsive processes, and is supported in terms 
of health and safety aspects by other health law instruments. The success of the regulatory 
scheme, in terms of being seen as transparent, fair and legitimate, will be largely left to the 
Advisory Committee who will need to be on the constant look out for ‘fine-tuning’.
New Zealand’s bi-cultural identity necessitates consideration of issues emerging from the 
use of novel technology from at least two cultural perspectives. These may be harmonious 
or discordant depending on a multitude of factors, adding a level of complexity which may 
be less noticeable in mono-cultural societies. Social research which investigates perceptions, 
experiences and attitudes relating to assisted reproduction is vital to deliberation in applied 
ethics.  Any ethical analysis and resultant policy which does not consider these would unlikely 
be effective or may lead to unintended consequences.
New Zealand is renowned for its thorough investigation of issues surrounding the 
implementation of novel technologies as was seen in the Royal Commission of Inquiry into 
Genetic Modification. There is, however, a comparative dearth of research investigating issues 
surrounding individual perceptions, experiences, and attitudes relating to new human assisted 
reproductive technologies.
Caution should be exercised before directly applying the findings or knowledge arising 
from research investigating public groups overseas to the New Zealand situation. The main 
concerns which have emerged from social research into PGD in other countries include, but 
are not limited to, its potential impact on the following: pre-natal life, children, people with 
disabilities, those involved in making reproductive decisions, women, men, communities, and 
family relationships.
The creation of fair and relevant criteria with which to evaluate public views is extremely 
difficult and has in the past resulted in the marginalising of relevant groups, such as children 
and people with disabilities.  This, coupled with the consultation requirement built into the 
HART Act, highlights the importance of specific social and ethical research into assisted 
reproduction in New Zealand. Such research will greatly enhance the level of ethical debate 
and also the value and durability of policy and legislation in these areas.
When there are strongly held positions on either side of a debate such as there is on PGD, a 
common situation in a democracy is to go with the majority view.  However, the meaning of 
democracy needs refinement and   the following comment from H.L.A. Hart, the Oxford legal 
philosopher, gives us pause for reflection:
“It seems feasibly easy to believe that democratic principles entails acceptance of what may 
be termed moral populism: the view that the majority have a moral right to dictate how 
all should live … The central mistake is a failure to distinguish the acceptable principle 
that political power is best entrusted to the majority from the unacceptable claim that 
what the majority do with that power is beyond criticism and must never be resisted.  No 
one can be a democrat who does not accept the first of these, but no democrat need accept 
the second”.29
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At present, PGD has the most dramatic impact on a small minority of families.  Their voices 
and concerns can easily be lost.  This report critiques majority positions which unjustifiably or 
inconsistently erode family choices.
Mark Henaghan and sheila Mclean
(with thanks to Richman Wee and to all project members for their input into this chapter)
June 2006
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